{
    "id": 26073,
    "fullName": "BAP1 dec exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "BAP1 dec exp indicates decreased expression of the Bap1 protein and/or mRNA. However, the mechanism causing the decreased expression is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 8314,
        "geneSymbol": "BAP1",
        "terms": [
            "BAP1",
            "HUCEP-13",
            "hucep-6",
            "UCHL2"
        ]
    },
    "variant": "dec exp",
    "createDate": "02/16/2017",
    "updateDate": "02/16/2017",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 9966,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, an osteosarcoma cell line with decreased expression of BAP1 via shRNA demonstrated sensitivity to treatment with Veliparib (ABT-888) in culture, resulting in decreased cell survival (PMID: 24894717).",
            "molecularProfile": {
                "id": 27219,
                "profileName": "BAP1 dec exp"
            },
            "therapy": {
                "id": 954,
                "therapyName": "Veliparib",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6379,
                    "pubMedId": 24894717,
                    "title": "Germline mutations in BAP1 impair its function in DNA double-strand break repair.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24894717"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9962,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, knockdown of Bap1 with siRNA in mesothelioma cells resulted in increased sensitivity to Zolinza (vorinostat) in culture (PMID: 25970771).",
            "molecularProfile": {
                "id": 27219,
                "profileName": "BAP1 dec exp"
            },
            "therapy": {
                "id": 1077,
                "therapyName": "Vorinostat",
                "synonyms": null
            },
            "indication": {
                "id": 1790,
                "name": "malignant mesothelioma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7826,
                    "pubMedId": 25970771,
                    "title": "Loss of the deubiquitylase BAP1 alters class I histone deacetylase expression and sensitivity of mesothelioma cells to HDAC inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25970771"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9963,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, knockdown of Bap1 with siRNA in mesothelioma cells resulted in increased sensitivity to Mocetinostat (MGCD0103) in culture (PMID: 25970771).",
            "molecularProfile": {
                "id": 27219,
                "profileName": "BAP1 dec exp"
            },
            "therapy": {
                "id": 3002,
                "therapyName": "Mocetinostat",
                "synonyms": null
            },
            "indication": {
                "id": 1790,
                "name": "malignant mesothelioma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7826,
                    "pubMedId": 25970771,
                    "title": "Loss of the deubiquitylase BAP1 alters class I histone deacetylase expression and sensitivity of mesothelioma cells to HDAC inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25970771"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 27219,
            "profileName": "BAP1 dec exp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}